Children with Prader-Willi syndrome (PWS) show alterations in each phase of infantile, childhood and pubertal growth when compared to the normal population. Growth Hormone (GH) therapy is recommended due to reported improvements in height velocity, muscle tone and body composition. This evidence has been reflected in a change in our clinical practice during the last 5 years: increased prescribing of GH and initiation of GH at a younger age. 
• Three phases of growth were observed: 1-5 years, with acceleration in both Height SDS and BMI SDS; 6-12 years, with stabilisation in both Height SDS and BMI SDS; and 13-18 years, with deceleration in Height SDS and no change in BMI SDS.
• Children in the 2013-2017 period were taller at the age of 5 years and they were also taller and with a lower BMI SDS at the age of 12 years • Growth hormone therapy improved Height SDS each year during the first two years of therapy. Height Velocity SDS improved during first year of therapy and was then maintained during the second year. BMI increased in the year prior to Growth hormone therapy and was stabilised after Growth hormone initiation. Growth and syndromes (to include Turner syndrome)
